Key facts
- This page summarizes Vincent O'Neill's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Dec 2024, 18:10.
Vincent O'Neill - 14 Dec 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- Executive Vice President, Chief of Product Development and Medical Officer
- Issuer ticker
- BTAI
- Reported as of
- 14 Dec 2024
- Net transaction value
- -$58.13
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2024, 18:10:14 UTC
- Prior SEC filing
- 03 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Steinhart, as Attorney in Fact for Vincent O'Neill
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vincent O'Neill filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 17 Dec 2024.
Change
- Previous filing in this sequence was filed on 03 Oct 2024.
- Current net transaction value: -$58.13.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTAI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +521
- Change %
- +2.7%
- Price
- Shares after
- 20,122
- Date
- 14 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
BTAI
transaction
Common Stock
Sale
- Transaction value
- $58.13
- Shares
- -165
- Change %
- -0.82%
- Price
- $0.3523
- Shares after
- 19,957
- Date
- 16 Dec 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTAI
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -521
- Change %
- -17%
- Price
- $0.000000
- Shares after
- 2,606
- Date
- 14 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 521
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
Footnote F3
On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
SEC remarks
Executive Vice President, Chief of Product Development and Medical Officer